MRG-110 / Viridian Therap - LARVOL DELTA

Epigenetic regulation of angiogenesis and its therapeutics. (PubMed, Genomics Inform) - "In recent years, epigenetic drugs, such as DNA methyltransferase inhibitors (e.g., azacitidine, decitabine), histone deacetylase inhibitors (e.g., vorinostat, romidepsin), and BET inhibitors (e.g., JQ1), have emerged as promising therapeutic strategies for targeting abnormal angiogenesis...Additionally, miRNA modulators, such as MRG-110 and MRG-201, provide precise regulation of angiogenesis-related pathways, demonstrating significant therapeutic potential in preclinical models. This review underscores the intricate interplay between epigenetic regulation and angiogenesis, highlighting key mechanisms and therapeutic applications. Advancing our understanding of these processes will enable the development of more effective and targeted epigenetic therapies for angiogenesis-related diseases, paving the way for innovative clinical interventions."

Journal • Review • Atherosclerosis • Cardiovascular • Diabetic Retinopathy • Gene Therapies • Oncology • Retinal Disorders

Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. (PubMed, Nucleic Acid Ther) - "MRG-110 is a locked nucleic acid-based antisense oligonucleotide that targets miR-92a-3p and experimentally was shown to have documented therapeutic effects on cardiovascular disease and wound healing...Single-cell RNA sequencing of peripheral blood cells revealed a cell type-specific derepression of miR-92a targets. Together this study demonstrates that systemic infusion of anti-miR-92a efficiently inhibits miR-92a in the peripheral blood compartment and derepresses miR-92a targets in humans."

Journal • P1 data • Cardiovascular • CD31 • ITGA5

miRagen Announces First Quarter 2019 Financial Results and Provides Corporate Update (GlobeNewswire, Miragen Therapeutics, Inc.) - "MRG-110 is currently being evaluated in collaboration with Servier in two Phase 1 clinical trials designed to evaluate the safety, tolerability, and pharmacokinetics of MRG-110. The data generated in these clinical trials is expected to provide clinically translatable biomarkers that may support future clinical trials for the treatment of heart failure and other conditions...such as complicated lacerations in high risk patients and burns. Enrollment has been completed in both Phase 1 clinical trials of MRG-110 and the Company expects to report data in 2019."

Enrollment closed • P1 data

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers (clinicaltrials.gov) - P1; N=42; Completed; Sponsor: miRagen Therapeutics, Inc.; Recruiting ➔ Completed

Clinical • Trial completion

Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers (clinicaltrials.gov) - P1; N=49; Completed; Sponsor: Institut de Recherches Internationales Servier; Recruiting ➔ Completed

Clinical • Trial completion